Abstract 1534: MEDI5083, a novel CD40L-Fc fusion protein, activates the CD40 pathway on antigen presenting cells and promotes a robust anti-tumor immune response in a B16F10 murine tumor model
Sign Up to like & getrecommendations! Published in 2019 at "Immunology"
DOI: 10.1158/1538-7445.am2019-1534
Abstract: Targeting CD40 with its natural ligand (CD40L) enhances the immune-stimulatory functions of dendritic cells, B cells, monocytes and macrophages, resulting in T cell priming, expansion and differentiation. Thus, activation of the CD40 pathway is an… read more here.
Keywords: anti tumor; medi5083; tumor immune; cd40 pathway ... See more keywords